Type I and II Interferons in the Anti-Tumor Immune Response
Open Access
- 2 March 2021
- Vol. 13 (5), 1037
- https://doi.org/10.3390/cancers13051037
Abstract
The interferons (IFNs) are essential components of the immune response against infections and malignancies. IFNs are potent promoters of the anti-tumor response, but there is also evidence that feedback mechanisms regulated by IFNs negatively control immune responses to avoid hyper-activation and limit inflammation. This balance of responses plays an important role in cancer surveillance, immunoediting and response to anticancer therapeutic approaches. Here we review the roles of both type I and type II IFNs on the control of the immune response against malignancies in the context of effects on both malignant cells and cells of the immune system in the tumor microenvironment.Keywords
Funding Information
- National Cancer Institute (R01-CA77816, R01-CA121102, R21-CA245447)
- U.S. Department of Veterans Affairs (I01-CX000916)
This publication has 201 references indexed in Scilit:
- Enhanced Dendritic Cell-Mediated Antigen-Specific CD4+ T Cell Responses: IFN-Gamma Aids TLR StimulationJournal of Drug Delivery, 2013
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumorsProceedings of the National Academy of Sciences, 2012
- The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implicationsCurrent Opinion in Immunology, 2012
- CD8+ T Cells: Foot Soldiers of the Immune SystemImmunity, 2011
- Inflammatory signaling compromises cell responses to interferon alphaOncogene, 2011
- Inflammation driven by tumour-specific Th1 cells protects against B-cell cancerNature Communications, 2011
- Interferon-γ links ultraviolet radiation to melanomagenesis in miceNature, 2011
- Inflammatory cytokines as a third signal for T cell activationCurrent Opinion in Immunology, 2010
- An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancerProceedings of the National Academy of Sciences, 2008
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002